Biohaven Statistics
Total Valuation
Biohaven has a market cap or net worth of $2.06 billion. The enterprise value is $2.20 billion.
| Market Cap | 2.06B |
| Enterprise Value | 2.20B |
Important Dates
The last earnings date was Thursday, October 29, 2026, after market close.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biohaven has 151.06 million shares outstanding. The number of shares has increased by 38.50% in one year.
| Current Share Class | 151.06M |
| Shares Outstanding | 151.06M |
| Shares Change (YoY) | +38.50% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 10.94% |
| Owned by Institutions (%) | 82.72% |
| Float | 116.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 13.08 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.05
| Current Ratio | 3.05 |
| Quick Ratio | 2.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -90.57% |
| Return on Invested Capital (ROIC) | -122.06% |
| Return on Capital Employed (ROCE) | -242.63% |
| Weighted Average Cost of Capital (WACC) | 18.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.98M |
| Employee Count | 274 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Biohaven has paid $950,000 in taxes.
| Income Tax | 950,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +74.34% in the last 52 weeks. The beta is 3.13, so Biohaven's price volatility has been higher than the market average.
| Beta (5Y) | 3.13 |
| 52-Week Price Change | +74.34% |
| 50-Day Moving Average | 13.52 |
| 200-Day Moving Average | 12.33 |
| Relative Strength Index (RSI) | 48.03 |
| Average Volume (20 Days) | 3,754,614 |
Short Selling Information
The latest short interest is 15.01 million, so 9.94% of the outstanding shares have been sold short.
| Short Interest | 15.01M |
| Short Previous Month | 19.05M |
| Short % of Shares Out | 9.94% |
| Short % of Float | 12.88% |
| Short Ratio (days to cover) | 4.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -487.47M |
| Pretax Income | -541.73M |
| Net Income | -542.68M |
| EBITDA | -478.05M |
| EBIT | -487.47M |
| Earnings Per Share (EPS) | -$3.81 |
Balance Sheet
The company has $161.13 million in cash and $300.44 million in debt, with a net cash position of -$139.32 million or -$0.92 per share.
| Cash & Cash Equivalents | 161.13M |
| Total Debt | 300.44M |
| Net Cash | -139.32M |
| Net Cash Per Share | -$0.92 |
| Equity (Book Value) | -98.25M |
| Book Value Per Share | -0.65 |
| Working Capital | 128.75M |
Cash Flow
In the last 12 months, operating cash flow was -$472.53 million and capital expenditures -$642,000, giving a free cash flow of -$473.17 million.
| Operating Cash Flow | -472.53M |
| Capital Expenditures | -642,000 |
| Depreciation & Amortization | 9.42M |
| Net Borrowing | n/a |
| Free Cash Flow | -473.17M |
| FCF Per Share | -$3.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biohaven does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.50% |
| Shareholder Yield | -38.50% |
| Earnings Yield | -27.98% |
| FCF Yield | -22.26% |
Analyst Forecast
The average price target for Biohaven is $23.73, which is 74.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $23.73 |
| Price Target Difference | 74.23% |
| Analyst Consensus | Buy |
| Analyst Count | 17 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |